Yatharth Hospitals presents a compelling long-term healthcare investment case rooted in super-specialty infrastructure, geographic expansion.

The chain operates in North India with more than 2,300+ beds across 7–8 hospitals in Delhi NCR, Jhansi-Orchha, and Faridabad. Its facilities are well-accredited — NABH-certified for quality and its Greater Noida-West hospital has earned JCI accreditation, reinforcing its commitment to high clinical standards. Financially, Yatharth delivered ~ ₹880 cr in revenue for FY25, growing ~31% YoY, with PAT at ₹130.6 cr — up 14%. Even after adding new capacity, its cash conversion remained strong (~68%) and it generated ₹149.6 cr in operating cash flow. The management is aggressively scaling: it is acquiring a majority stake (~60%) in a 400-bed hospital in Faridabad, investing ~₹100 cr to bring in advanced super-specialty services like oncology and robotic surgery. Its business model is geared for growth: advanced diagnostic and surgical capabilities (CT, MRI, cath lab) , super-specialty services (cardiology, neuro, oncology) in key locations , and a patient-centric culture focused on trust, transparency, and high quality. As bed occupancy improves (FY25 saw occupancy rise to ~61%) and ARPOB (Average Revenue Per Occupied Bed) grows (₹30,829 in FY25, up 8% YoY), profitability could scale materially. In summary, Yatharth Hospitals is building a scalable super-specialty hospital chain in underpenetrated markets, driven by high-quality medical infrastructure, disciplined cash-flow generation, and aggressive expansion. For long-term investors who believe in India’s healthcare leap and rising demand for tertiary care, it’s a well-placed structural play.